, Tracking Stock Market Picks
Enter Symbol:
Genomic Health, Inc. (GHDX) [hlAlert]

down 2.02 %

Genomic Health, Inc. (GHDX) rated Underweight with price target $25 by Barclays

Posted on: Wednesday,  Sep 2, 2015  1:25 PM ET by Barclays

Barclays rated Underweight Genomic Health, Inc. (NASDAQ: GHDX) on 09/02/2015, when the stock price was $26.19. Since
then, Genomic Health, Inc. has gained 2.06% as of 01/06/2016's recent price of $26.73.
If you would have followed this Barclays's recommendation on GHDX, you would have lost 2.02% of your investment in 126 days.

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/2/2015 1:25 PM Sell
26.19 25.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy